Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
Interventional Cardiology
Medical & Preventive Cardiology
Lipidology & Atherosclerosis Prevention
CV RISK/DIABETES
A MULTI-SPECIALTY PERSPECTIVE
  • close
CMEducation Resources iQ&A
  • person
  • Home
  • Specialtieschevron_right
    • chevron_leftTopics
    • PCSK9s in Interventional Cardiology
    • PCSK9s in Medical and Preventive Cardiology
    • Lipidology & Atherosclerosis Prevention
    • CV Risk/Diabetes
    • A Multi-Specialty Perspective
  • Submit A Question
close

Andreas Zeiher, MD

Andreas Zeiher, MD

Chairman of Medicine
Department of Cardiology, Angiology, and Nephrology
J. W. Goethe University
Frankfurt, Germany


Related Videos

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions? Video

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk? Video

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients? Video

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab? Video

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

In the interventional cardiology setting, what percentage of your patients do not achieve the ESC Lipid Guideline goal of 70 mg/dL and, therefore, are suitable candidates for PCSK9 inhibition? Can you discuss your patient selection process? Video

In the interventional cardiology setting, what percentage of your patients do not achieve the ESC Lipid Guideline goal of 70 mg/dL and, therefore, are suitable candidates for PCSK9 inhibition? Can you discuss your patient selection process?

From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level <50 mg/dL with a PCSK9 inhibitor? Video

From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level <50 mg/dL with a PCSK9 inhibitor?

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BroadcastMedBROADCASTMED